Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | CBS | P35520 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294625 | 1.00 | TSHR (0.33) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL21390150 | 1.00 | TSHR (0.33) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL22614110 | 0.79 | TSHR (0.35) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL25475513 | 0.79 | TSHR (0.35) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL20721981 | 0.79 | TSHR (0.35) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL20179864 | 0.78 | CHRM4 (0.33) | ITGB3ITGA2BPTGIR | |
| SCHEMBL25961307 | 0.77 | TSHR (0.33) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL21384165 | 0.77 | TSHR (0.33) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL21384269 | 0.77 | ITGB3 (0.31) | TSHRCTHCBSTHPOITGB3 | |
| SCHEMBL20722005 | 0.77 | ITGB3 (0.33) | TSHRCTHCBSTHPOITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | TSHR 4015/4885CTH 2811/4885CBS 3144/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | TSHR 4015/4885CTH 2811/4885CBS 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.